Mariella Grasso

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Antonio Palumbo, Tommaso Caravita, Emanuela Merla et al. · The Lancet · 2006 · 808 citations

Medicine, Oncology, Pharmacology +17

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Antonio Palumbo, Davide Rossi, Maide Cavalli et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

Medicine, Hematology, Oncology +17

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Alessandra Larocca, Davide Rossi, Maide Cavalli et al. · Blood · 2010 · 382 citations · Full text

Medicine, Hematology, Pharmacology +14

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Michèle Cavo, Lucia Pantani, Maria Teresa Petrucci et al. · Blood · 2012 · 309 citations · Full text

Medicine, Hematology, Pharmacotherapy +16